Specific antagonists of VEGF for neoadjuvant and adjuvant Therapy and neoadjuvant Treatment of tumors and the treatment of tumors in early stages

摘要

1. - a Pharmaceutical composition comprising an effective amount of a specific antagonist of VEGF for use in the treatment of metastatic cancer, benign Precancerous or not. 2.The pharmaceutical Composition of claim 1, wherein the specific antagonist of VEGF is in an amount effective to prevent the metastatic cancer, benign Precancerous or not become invasive cancer or metastatic. 3.The pharmaceutical Composition of claim 1, wherein Said benign Precancerous or non metastatic cancer, is a cancer of Stage 0 Stage, stage I or II. 4.The pharmaceutical Composition of claim 3, wherein the specific antagonist of VEGF is in an amount effective to prevent the benign cancer, Precancerous or not progress to metastatic cancer Stage III or IV stage. 5.The pharmaceutical Composition of claim 1, wherein the specific antagonist of VEGF is in an amount effective to reduce the size of tumor. 6.A Pharmaceutical composition comprising a specific antagonist of VEGF for use in the treatment of a subject with a Family History of cancer, polyps, or a Hereditary Cancer Syndrome, where the specific antagonist of VEGF is in an amount effective to prevent L To the occurrence or recurrence of a benign metastatic cancer, Precancerous or not in that subject. 7.The pharmaceutical Composition of claim 6, wherein the specific antagonist of VEGF is in a sufficient amount to prevent the occurrence or recurrence of the Cancer, benign Precancerous or not metastatic in a Subject that has never had clinically detectable cancer Or a guy who has had cancer, benign. 8.A Pharmaceutical composition comprising a specific antagonist of VEGF for use in reducing the size of the tumor in a subject with an unresectable tumor, where the specific antagonist of VEGF is in an amount effective to reduce the size of the tumor, allowing ACE If complete resection of the tumor. 9.The pharmaceutical Composition of claim 8, further use after complete resection of the tumor.